GSK plc (LON:GSK) Stock Rated “Hold” by Sell-Side Analysts

Shares of GSK plc (LON:GSK) have been given an average recommendation of “Hold” by the eight research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is GBX 2,064.38.

A number of research analysts have weighed in on the company. Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 1,975 target price on shares of GSK in a report on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a research note on Tuesday, September 29th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,500 price target on shares of GSK in a research report on Wednesday, July 29th. Finally, Berenberg Bank upped their price target on GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research note on Tuesday, September 15th.

Insiders Place Their Bets

In other GSK news, insider Jonathan Symonds purchased 1,500 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The stock was bought at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal purchased 637 shares of the stock in a transaction that occurred on Friday, September 18th. The shares were acquired at an average cost of GBX 4,985 per share, with a total value of £31,754.45. In the last 90 days, insiders have bought 2,144 shares of company stock worth $6,009,566. Company insiders own 0.20% of the company’s stock.

GSK Stock Up 0.4%

Shares of LON GSK opened at GBX 1,772 on Wednesday. The firm has a fifty day simple moving average of GBX 1,870.41 and a two-hundred day simple moving average of GBX 1,937.17. GSK has a 12 month low of GBX 1,592 and a 12 month high of GBX 2,282. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. The firm has a market capitalization of £71.00 billion, a PE ratio of 15.04, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK) last announced its earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Equities analysts expect that GSK will post 175.980975 earnings per share for the current year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.